Sonoma Pharmaceuticals, Inc. Stock News

BOULDER, CO / ACCESS Newswire / November 13, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal health care, today announced that Reliefacyn® Advanced...

BOULDER, CO / ACCESS Newswire / November 6, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it wi...

Revenues increased 57% for the quarter and 38% for the six months ended September 30, 2025 compared to same periods last year U.S. revenue increased 115% for the quarter and 86% for the six months ended September 30, 2025 compared to same periods last year Net loss per share decreased 46% for the quarter and 42% for the six months ended September 30, 2025 compared to same periods last year BOUL...

BOULDER, CO / ACCESS Newswire / October 14, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader in developing and producing stabilized hypochlorous acid (HOCl) products based on its patented Microcyn® technology, today announced the launch of a new HOCl wound cleanser manufactured by Sonoma for Medline Industries, LP. The product will be distributed by Medline into hos...

BOULDER, COLORADO / ACCESS Newswire / October 7, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products, today announced that it has successfully registered its manufacturing facility and listed its Microcyn-based facial spray under the FDA's Modernization of Cosmetic...

BOULDER, COLORADO / ACCESS Newswire / September 25, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal health care, today announced that it will parti...

BOULDER, CO / ACCESS Newswire / August 26, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal health care, today announced that Reliefacyn® Advanced I...

BOULDER, CO / ACCESS Newswire / August 13, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the launch ...